Peter Thompson Buys Shares of ARS Pharmaceuticals, Inc.
Insider Peter Thompson purchased 30,000 shares of ARS Pharmaceuticals on June 24, 2026.
Key Points
- Insider Peter Thompson bought 30,000 shares of ARS Pharmaceuticals, Inc. (SPRY) on June 24, 2026.
- Shares of SPRY traded near $8.54 on Saturday with a market cap of $848 million and a 52-week range of $6.66 to $18.90.
- Analysts maintain a 'strong buy' consensus with a target mean price of $28.40, following recent buys by insiders.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Insider Peter Thompson recently bought 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026. This transaction was not part of a pre-planned trading scheme. The stock traded near $8.54 on Saturday.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
On June 24, 2026, several insiders, including Peter Thompson, Laura Shawver, Rajeev Dadoo, Brent Saunders, and Saqib Islam, each bought 30,000 shares of ARS Pharmaceuticals. These transactions were not conducted under Rule 10b5-1 plans, indicating they were discretionary buys.
Other Institutional Activity in ARS Pharmaceuticals
Rubric Capital Management LP increased its holdings in ARS Pharmaceuticals by 1.8 million shares, ending with 8 million shares worth about $64.24 million, a 29% increase. Millennium Management LLC also boosted its position significantly, adding 2.8 million shares for a total of 5.98 million shares valued at approximately $48.04 million, marking an 88.8% increase. In contrast, BlackRock, Inc. slightly reduced its stake by 73,063 shares to hold 5.01 million shares worth around $40.25 million, a 1.4% decrease.
ARS Pharmaceuticals, Inc. Stock Up 45.0%
Shares of ARS Pharmaceuticals, Inc. (SPRY) traded near $8.54 on Saturday. The company has a market cap of approximately $848 million and a beta of 0.826, indicating its stock is less volatile than the market. The stock's 52-week range is between $6.66 and $18.90, with a 50-day moving average of $8.70 and a 200-day moving average of $9.36. ARS Pharmaceuticals maintains strong liquidity with a current ratio of 4.943 and a quick ratio of 4.645, although it has a high debt-to-equity ratio of 279.238.
$SPRY stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its 'buy' rating on ARS Pharmaceuticals with a price target of $24. Cantor Fitzgerald also maintained a 'buy' rating with a target of $30 on May 28, 2026. The stock has a consensus recommendation of 'strong buy' among analysts, with a target mean price of $28.40 based on five analyst opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California. It focuses on developing and commercializing treatments for severe allergic reactions. The company's flagship product, neffy, is a needle-free intranasal delivery system for epinephrine, used in emergency treatment of anaphylaxis. Founded in 2015, ARS Pharmaceuticals is led by CEO Richard E. Lowenthal and employs 154 people.
Bottom Line
Insider buying at ARS Pharmaceuticals, including recent purchases by Peter Thompson and others, suggests confidence in the company's prospects. With a strong 'buy' consensus from analysts and a focus on innovative treatments for allergic reactions, ARS Pharmaceuticals remains a company to watch. Keep in mind that insider transactions and 13F filings are backward-looking and may not reflect current positions.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.